Prognostic significance of HER‐2/neu oncoprotein expression in node‐positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

Cancer

Volumn 73, Issue 9, 1994, Pages 2359-2365

  Tětu, Bernard ^a   Brisson, Jacques ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

adjuvant therapy; breast carcinoma; HER 2 neu oncoprotein; immunohistochemistry

Indexed keywords

CATHEPSIN D; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; HEAT SHOCK PROTEIN; METHOTREXATE; ONCOPROTEIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, INFILTRATING DUCT; CELL MEMBRANE; CHEMOTHERAPY, ADJUVANT; CYTOPLASM; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGE; ONCOGENE PROTEINS, VIRAL; PROGNOSIS; RECEPTOR, ERBB-2; SUPPORT, NON-U.S. GOV'T; SURVIVAL RATE; TAMOXIFEN;

EID: 0028301750     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19940501)73:9<2359::AID-CNCR2820730919>3.0.CO;2-9     Document Type: Article

References (38)

1. The neu(c‐erbB‐2) oncogene
2. Follow‐up study of HER‐2/neu amplification in primary breast cancer
3. Studies of the HER‐2/neu proto‐oncogene in human breast and ovarian cancer
4. c‐myc Amplification is a better prognostic factor than HER‐2/neu amplification in primary breast cancer
5. Human breast cancer: correlation of relapse and survival with amplification of the HER‐2/neu oncogene
6. c‐erbB‐2 amplification in node‐negative human breast cancer
7. Correlation between long‐term survival in breast cancer patients and amplification of two putative oncogene‐coamplification units: hst‐1/int‐2 and c‐erbB‐2/ear‐1
8. Amplification of c‐erbB‐2 and aggressive human breast tumors?
9. Amplification of the c‐erb B‐2 oncogene and prognosis of breast adenocarcinoma
10. Increased erbB‐2 gene copies and expression in multiple stages of breast cancer
11. HER‐2/neu oncogene protein and prognosis in breast cancer
12. Overexpression of the c‐ erbB‐2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification
13. Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c‐erbB‐2 overexpression
14. HER‐2/neu in node‐negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma
15. Analysis of c‐erbB‐2 expression in breast carcinomas with clinical follow‐up
16. An immunohistochemical evaluation of c‐erbB‐2 expression in human breast carcinoma
17. Prognostic significance of HER‐2/neu expression in breast cancer and its relationship to other prognostic factors
18. Association of c‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer
19. Immunohistochemical assay of neu/c‐erbB‐2 oncogene product in paraffin‐embedded tissues in early breast cancer: retrospective follow‐up study of 245 stage I and II cases
20. The long term prognostic significance of c‐erbB‐2 in primary breast cancer
21. Prognostic importance of c‐erbB‐2 expression in breast cancer
22. c‐erbB‐2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes
23. Prognostic significance of HER‐2 oncoprotein expression in breast cancer: a 30‐year follow‐up
24. Expression of c‐erbB‐2 oncoprotein: a prognostic indicator in human breast cancer
25. NEU‐protein overexpression in breast cancer
26. Pathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of erbB‐2 protein overexpression in primary breast cancer
27. Expression of the HER‐2/neu proto‐oncogene in serous ovarian neoplasms
28. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues
29. c‐erbB‐2 oncoprotein expression in primary human tumors
30. Pathologic findings from the national surgical adjuvant project for breast cancers ( protocol no. 4): discriminants for tenth year treatment failure
31. Use of avidin‐biotin‐peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures
32. DNA flow cytometry in solid tumors: practical aspects and clinical applications
33. Nonparametric estimation from incomplete observations
34. Regression models and life‐tables (with discussion)
35. Immunohistochemical expression of NEU oncoprotein in breast carcinomas
36. The NEU‐oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients
37. Prognostic significance of cathepsin D expression in node‐positive breast carcinoma: an immunohistochemical study